GlassScriptPhysician profile
William C Klindt
NPI 1093904005
$8,474.85
in general payments reported to CMS, 2019-2025
24 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 93% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $790 · 2021: $938 · 2022: $1,373 · 2023: $1,114 · 2024: $1,531 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,541.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,650.61 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,215.26 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $786.15 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $752.38 | 2019-2025 | Trintellix |
| Lundbeck LLC | $734.29 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $720.05 | 2022-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $368.59 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $316.42 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $275.07 | 2021-2024 | Qelbree, Qelbree |
| Bausch Health US, LLC | $221.26 | 2019-2024 | Aplenzin |
| Axsome Therapeutics, INC. | $207.76 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $192.71 | 2019-2024 | |
| Allergan, INC. | $190.35 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $183.01 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $169.38 | 2020-2024 | Spravato |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $97.23 | 2024 | Brainsway Deep Tms System |
| Corium, LLC | $88.67 | 2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $76.12 | 2023-2024 | Quviviq |
| Tris Pharma INC | $72.94 | 2021-2023 | Dyanavel Xr |
| Shire North American Group INC | $61.14 | 2019 | |
| Vertical Pharmaceuticals, LLC | $34.76 | 2019 | |
| Eisai INC. | $20.81 | 2021 | |
| Arbor Pharmaceuticals, INC. | $20.62 | 2020 | |
| Collegium Pharmaceutical, INC. | $19.27 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Klindt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.